Radium-223 for the treatment of bone metastasis of prostate cancer / 中华男科学杂志
National Journal of Andrology
;
(12): 78-81, 2017.
Artigo
em Chinês
| WPRIM
| ID: wpr-812805
ABSTRACT
Over 80% of the patients with prostate cancer (PCa) develop bone metastasis, which seriously affects the patients' quality of life and remains a major cause of morbidity. Radium-223 (Ra-223), a newly approved agent targeting bone metastasis of PCa, can improve the quality of life and prolong the overall survival of the PCa patients with bone metastasis. This article presents an overview of the clinical trials recently published on the management of bone metastasis of PCa with Ra-223.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Patologia
/
Neoplasias da Próstata
/
Qualidade de Vida
/
Radioisótopos
/
Radioterapia
/
Neoplasias Ósseas
/
Ensaios Clínicos como Assunto
/
Rádio (Elemento)
/
Usos Terapêuticos
Limite:
Humanos
/
Masculino
Idioma:
Chinês
Revista:
National Journal of Andrology
Ano de publicação:
2017
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS